Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 6;20(6):e0325384.
doi: 10.1371/journal.pone.0325384. eCollection 2025.

How trustworthy and applicable is the evidence from systematic reviews of depression treatments: Protocol for systematic examination

Affiliations

How trustworthy and applicable is the evidence from systematic reviews of depression treatments: Protocol for systematic examination

Iwo Fober et al. PLoS One. .

Abstract

Background: Depression is a common mental disorder significantly impacting daily functioning. Standard treatments include drugs, psychotherapies, or a combination of both. Treatment selection relies on scientific evidence, though the trustworthiness and applicability of this evidence can vary.

Objectives: This protocol presents a method to evaluate evidence from systematic reviews for pharmacological and psychological treatments for depression, focusing on trustworthiness and applicability structured into five components: quality of conduct and reporting, risk of bias, spin in abstract conclusions, robustness of meta-analytical results, heterogeneity and clinical diversity.

Methods: We will conduct a systematic search of systematic reviews in MEDLINE, Embase, PsycInfo, and Cochrane Database of Systematic Reviews. Our focus will be on systematic reviews of first-line treatments for depression in adults, including antidepressants, psychotherapy, or combined treatments, compared to either active or inactive comparators. We will extract information needed for a comprehensive methodological evaluation using qualitative tools, including AMSTAR 2, ROBIS, Conflict-of-Interest assessment, Referencing Framework for SRs, Spin Measure, and heterogeneity exploration assessment. For quantitative analyses, such as Fragility Index, Ellipse of Insignificance, Region of Attainable Redaction, GRIM test, Leave-N-Out analysis, and prediction intervals, we will select and recalculate two meta-analyses per review. We define a set of outcomes to enable practical and intuitive interpretation of these analyses' results. Descriptive statistics, non-parametric statistical tests, and narrative summaries will be used to synthesize and compare outcomes across several pre-specified subgroups.

Expected outcomes: We expect these analyses to provide an enhanced perspective on the practice of evidence synthesis in the field of mental health, offer methodological guidance for future systematic reviews and meta-analyses, and contribute to improved informed decision-making by clinicians and patients.

Osf registration: osf.io/7f9cj and osf.io/ynejs.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Study workflow leading to the assessment of quality of conduct and reporting, risk of bias and spin in abstract conclusions.
Fig 2
Fig 2. Study workflow leading to the assessment of heterogeneity and clinical diversity, and robustness of meta-analytical results.

Similar articles

References

    1. Depressive disorder (depression). Accessed 2025 January 29. https://www.who.int/news-room/fact-sheets/detail/depression
    1. McKibbon KA. Evidence-based practice. Bull Med Libr Assoc. 1998;86(3):396–401. - PMC - PubMed
    1. Tenny S, Varacallo M. Evidence-based medicine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. - PubMed
    1. Gupta M. Is evidence-based psychiatry ethical? Oxford: Oxford University Press; 2014.
    1. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al.. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525. doi: 10.1177/0269881115581093 - DOI - PubMed

Substances